Altus Pharmaceuticals reaffirms plan to submit NDA for Trizytek



Scientists investigating the 2006 Northwick Park drug-trial disaster that left six healthy volunteers hospitalised say they have developed new pre-clinical tests that could have stopped the trial from ever going ahead. But Dr Stephen Poole, speaking at the British Pharmacological Society’s Winter Meeting in Brighton, said that research is still “ongoing” to understand why the

Full Post: Lessons from Northwick Park drug-trial disaster

Altus Pharmaceuticals Inc. announced today that it is reaffirming its plan to submit a new drug application (NDA) for Trizytek (liprotamase) in the first-half of 2009.

Trizytek is a non-porcine derived enzyme replacement therapy for patients with pancreatic insufficiency.

Based on a positive FDA response to Altus’ pre-NDA meeting submission material, Altus and the FDA have agreed that the Trizytek clinical development program supports submission of a license application for Trizytek. In the pre-NDA meeting package, Altus provided the FDA comprehensive data from its completed Phase 3 efficacy and Phase 2 studies as well as interim safety and health-outcomes data from the ongoing Phase 3 studies to evaluate the long-term safety of Trizytek over one year of open-label treatment in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. As a result, the November pre-NDA meeting for Trizytek is no longer necessary and Altus’ previously stated timelines for the Trizytek NDA submission remain unchanged.

“With this communication from the FDA, we are reaffirming our goal of filing a new drug application for Trizytek in the first half of 2009. We are focusing our resources on moving all aspects of the Trizytek program forward, including the ongoing long-term safety study, which is on track to be completed in the first half of 2009,” stated Dr. Georges Gemayel, President and Chief Executive Officer of Altus Pharmaceuticals. “The outcome from our discussions with the FDA only strengthens our belief in the clinical benefit that Trizytek will bring to patients who require pancreatic enzyme replacement therapy. In addition, completing a corporate collaboration around Trizytek is key to our plan going forward and we believe this information will be an important part of the evaluation of the program by any potential partner.”

Altus’ Phase 3 Trizytek efficacy trial in patients with cystic fibrosis (CF) successfully met its primary endpoint of improvement in fat absorption with statistical significance. In August 2008, the Company released top-line results from its 163 patient, double-blind, placebo-controlled trial of Trizytek, which is a stable and pure combination of three active enzymes in a fixed-ratio that is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals. Trizytek was well-tolerated and had a favorable safety profile in the trial. There were no serious adverse events attributed to the Trizytek treatment. Altus’ Trizytek Phase 3 clinical program is the largest ever conducted to evaluate the efficacy and safety of pancreatic enzyme replacement therapy in cystic fibrosis patients.

Trizytek has the potential to be the first porcine-free enzyme replacement therapy for patients with pancreatic insufficiency. Pancreatic insufficiency is a condition that affects most cystic fibrosis patients, as well as many patients with chronic pancreatitis. In these diseases, a deficiency of pancreatic enzymes causes poor absorption of essential nutrients, which often leads to malnutrition, impaired growth and reduced survival. Trizytek is intended to replace missing digestive enzymes with one capsule per-meal to promote and maintain proper digestion and growth in affected patients. Altus is developing Trizytek to enhance health outcomes by offering significant patient advantages such as improved and more consistent dosing that we expect will drive better long-term compliance. Utilizing recombinant technology, Trizytek is manufactured by blending three drug substance enzymes: lipase, protease and amylase. This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals.

http://www.altus.com/

Link




Early detection of lung disease in cystic fibrosis (CF), combined with aggressive treatment in infants, may be the key to controlling the progression of the disease, according to a recent study. New research shows that contrary to previous scientific opinion, progressive lung damage in CF patients can begin as early as infancy even though lung

Full Post: Intervention in infants with cystic fibrosis key to slowing progression



Medicsight PLC has announced the submission of a 510(k) Premarket Notification to the United States Food and Drug Administration (FDA) for clearance to market its ColonCAD(TM) image analysis software throughout the U.S. Submission of the 510(k) notification enters Medicsight into a FDA review process. Successful clearance of the product will enable the Company to access

Full Post: Medicsight seeks FDA 510(k) clearance to market ColonCAD software in the U.S.



UC San Diego Medical Center is currently enrolling patients in a Phase 2 clinical trial of an investigational drug for the treatment of advanced heart failure. The “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease,” or CUPID, study is evaluating a new gene-based therapy designed to stimulate production of an enzyme that

Full Post: Trial of investigational drug for treatment of advanced heart failure



An enzyme that is overexpressed in pancreatic cancer cells may hold the key to successfully treating the disease with targeted immunotherapy, researchers from Thomas Jefferson University reported at the 2008 Annual Meeting of the Southern Surgical Association. Previous data show that a protein, indoleamine 2,3-dioxygenase (IDO), is overexpressed in pancreatic ductal adenocarcinomas, according to Jonathan

Full Post: Protein indoleamine 2,3-dioxygenase points to new pancreatic cancer therapies



Reata Pharmaceuticals, Inc. has announced that RTA 402 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. RTA 402 is currently being studied in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease.

Full Post: FDA grants orphan drug status to Reata’s pancreatic cancer drug